Combination tablets combining DPP-4 inhibitor sitagliptin with metformin hydrochloride for glycemic control in type 2 diabetes. Produced by generic and branded drug firms, distributed through B2B channels to healthcare facilities, pharmacies, and clinics for use by diabetologists and internal medicine